Tobacco-attributable disease remains the largest potentially modifiable cause of mortality. Strategies to reduce smoking prevalence include developing more effective smoking cessation treatments. In this study, researchers developed a compact laboratory assay for genotyping DNA samples with specific markers and software to analyze clinical and genomic data (Smokescreen TL).

Smokescreen TL will be validated in smokers in clinical care. Ultimately, Smokescreen TL will be available for use by health care providers interested in helping treatment seeking smokers quit.